Detalhe da pesquisa
1.
Loss of the HVEM Tumor Suppressor in Lymphoma and Restoration by Modified CAR-T Cells.
Cell
; 167(2): 405-418.e13, 2016 Oct 06.
Artigo
Inglês
| MEDLINE | ID: mdl-27693350
2.
GPRC5D-Targeted CAR T Cells for Myeloma.
N Engl J Med
; 387(13): 1196-1206, 2022 09 29.
Artigo
Inglês
| MEDLINE | ID: mdl-36170501
3.
Engineering CAR-T cells to activate small-molecule drugs in situ.
Nat Chem Biol
; 18(2): 216-225, 2022 02.
Artigo
Inglês
| MEDLINE | ID: mdl-34969970
4.
The "Great Debate" at Immunotherapy Bridge 2022, Naples, November 30th-December 1st, 2022.
J Transl Med
; 21(1): 275, 2023 04 22.
Artigo
Inglês
| MEDLINE | ID: mdl-37087493
5.
Interventions and outcomes of adult patients with B-ALL progressing after CD19 chimeric antigen receptor T-cell therapy.
Blood
; 138(7): 531-543, 2021 08 19.
Artigo
Inglês
| MEDLINE | ID: mdl-33851211
6.
Multipurposing CARs: Same engine, different vehicles.
Mol Ther
; 30(4): 1381-1395, 2022 04 06.
Artigo
Inglês
| MEDLINE | ID: mdl-35151842
7.
MEETING HIGHLIGHTS: THE THIRD MARIE SKLODOWSKA-CURIE SYMPOSIUM ON CANCER RESEARCH AND CARE AT ROSWELL PARK COMPREHENSIVE CANCER CENTER, BUFFALO, NY, SEPTEMBER 20-22, 2023.
Wiad Lek
; 76(12): 2543-2555, 2023.
Artigo
Inglês
| MEDLINE | ID: mdl-38290016
8.
Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia.
N Engl J Med
; 378(5): 449-459, 2018 02 01.
Artigo
Inglês
| MEDLINE | ID: mdl-29385376
9.
CD19 CAR T cells following autologous transplantation in poor-risk relapsed and refractory B-cell non-Hodgkin lymphoma.
Blood
; 134(7): 626-635, 2019 08 15.
Artigo
Inglês
| MEDLINE | ID: mdl-31262783
10.
Toxicity and response after CD19-specific CAR T-cell therapy in pediatric/young adult relapsed/refractory B-ALL.
Blood
; 134(26): 2361-2368, 2019 12 26.
Artigo
Inglês
| MEDLINE | ID: mdl-31650176
11.
Early experience using salvage radiotherapy for relapsed/refractory non-Hodgkin lymphomas after CD19 chimeric antigen receptor (CAR) T cell therapy.
Br J Haematol
; 190(1): 45-51, 2020 07.
Artigo
Inglês
| MEDLINE | ID: mdl-32135029
12.
GPRC5D-Targeted CAR T Cells for Myeloma. Reply.
N Engl J Med
; 387(24): 2296, 2022 12 15.
Artigo
Inglês
| MEDLINE | ID: mdl-36516098
13.
Correlation of IL-6 secretion and hyponatremia with the use of CD19+ chimeric antigen receptor T-cellsâ©.
Clin Nephrol
; 93(1): 42-46, 2020 Jan.
Artigo
Inglês
| MEDLINE | ID: mdl-31670650
14.
CAR T-cell therapy: Full speed ahead.
Hematol Oncol
; 37 Suppl 1: 95-100, 2019 Jun.
Artigo
Inglês
| MEDLINE | ID: mdl-31187533
15.
CARs of the future.
Am J Hematol
; 94(S1): S55-S58, 2019 05.
Artigo
Inglês
| MEDLINE | ID: mdl-30680777
16.
Development and Evaluation of an Optimal Human Single-Chain Variable Fragment-Derived BCMA-Targeted CAR T Cell Vector.
Mol Ther
; 26(6): 1447-1456, 2018 06 06.
Artigo
Inglês
| MEDLINE | ID: mdl-29678657
17.
Autologous CD19-Targeted CAR T Cells in Patients with Residual CLL following Initial Purine Analog-Based Therapy.
Mol Ther
; 26(8): 1896-1905, 2018 08 01.
Artigo
Inglês
| MEDLINE | ID: mdl-29910179
18.
Cytokine Release Syndrome Grade as a Predictive Marker for Infections in Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia Treated With Chimeric Antigen Receptor T Cells.
Clin Infect Dis
; 67(4): 533-540, 2018 08 01.
Artigo
Inglês
| MEDLINE | ID: mdl-29481659
19.
Building a CAR Garage: Preparing for the Delivery of Commercial CAR T Cell Products at Memorial Sloan Kettering Cancer Center.
Biol Blood Marrow Transplant
; 24(6): 1135-1141, 2018 06.
Artigo
Inglês
| MEDLINE | ID: mdl-29499327
20.
CD19-targeted CAR T-cell therapeutics for hematologic malignancies: interpreting clinical outcomes to date.
Blood
; 127(26): 3312-20, 2016 06 30.
Artigo
Inglês
| MEDLINE | ID: mdl-27207800